ID   FM82
AC   CVCL_C609
SY   FM-82
DR   cancercelllines; CVCL_C609
DR   Cosmic; 851404
DR   Cosmic; 1047679
DR   Cosmic; 1181749
DR   Cosmic; 2163778
DR   ECACC; 13012426
DR   ESTDAB; ESTDAB-027
DR   GEO; GSM156030
DR   IARC_TP53; 26105
DR   Progenetix; CVCL_C609
DR   Wikidata; Q54835067
RX   PubMed=9288767;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
RX   PubMed=27600516;
CC   HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*03:04,07:04; DPB1*04:01,03:01; DQB1*03:02,03:01:01; DRB1*04:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Proteomics; HLA class I peptidome.
CC   Omics: Variations; Array-based CGH.
ST   Source(s): ECACC=13012426; ESTDAB=ESTDAB-027
ST   Amelogenin: X
ST   CSF1PO: 14
ST   D13S317: 8 (ECACC=13012426)
ST   D13S317: 8,10 (ESTDAB=ESTDAB-027)
ST   D16S539: 11,13
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 11
ST   FGA: 24,25
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 20
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=27600516; DOI=10.1007/s00262-016-1897-3; PMCID=PMC5509013;
RA   Gloger A., Ritz D., Fugmann T., Neri D.;
RT   "Mass spectrometric analysis of the HLA class I peptidome of melanoma
RT   cell lines as a promising tool for the identification of putative
RT   tumor-associated HLA epitopes.";
RL   Cancer Immunol. Immunother. 65:1377-1393(2016).
//